Abstract
Immune checkpoint inhibitors (ICI), such as anti-PD-1, are used to facilitate anti-cancer function of effector T cells, which gives a passable treatment effect to patients, and CD8+ T cell exhaustion is a key impediment to ICI treatment. To improve anti-cancer effect of ICI, combination therapy is a potential strategy. Chemo-immunotherapy combination augments therapeutic efficacy of ICI, but elevated adverse effects are accompanied with patients. Thus, a tumor-microenvironment-on-chip (TMoC) system was developed to identify synergism with ICI therapy to maximize treatment efficacies while reducing the side effects.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
